Cargando…

Polytopic vaccination with a live-attenuated dengue vaccine enhances B-cell and T-cell activation, but not neutralizing antibodies

Dengue, caused by dengue viruses (DENVs), is the most common arboviral disease of humans. Several dengue vaccine candidates are at different stages of clinical development and one has been licensed. Inoculation with live-attenuated DENV constructs is an approach that has been used by vaccine develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunsawong, Taweewun, Wichit, Sineewanlaya, Phonpakobsin, Thipwipha, Poolpanichupatam, Yongyuth, Klungthong, Chonticha, Latthiwongsakorn, Napaporn, Thaisomboonsuk, Butsaya, Im-erbsin, Rawiwan, Yoon, In-Kyu, Ellison, Damon W., Macareo, Louis R., Srikiatkhachorn, Anon, Gibbons, Robert V., Fernandez, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367862/
https://www.ncbi.nlm.nih.gov/pubmed/28393119
http://dx.doi.org/10.1016/j.heliyon.2017.e00271
_version_ 1782517848228233216
author Hunsawong, Taweewun
Wichit, Sineewanlaya
Phonpakobsin, Thipwipha
Poolpanichupatam, Yongyuth
Klungthong, Chonticha
Latthiwongsakorn, Napaporn
Thaisomboonsuk, Butsaya
Im-erbsin, Rawiwan
Yoon, In-Kyu
Ellison, Damon W.
Macareo, Louis R.
Srikiatkhachorn, Anon
Gibbons, Robert V.
Fernandez, Stefan
author_facet Hunsawong, Taweewun
Wichit, Sineewanlaya
Phonpakobsin, Thipwipha
Poolpanichupatam, Yongyuth
Klungthong, Chonticha
Latthiwongsakorn, Napaporn
Thaisomboonsuk, Butsaya
Im-erbsin, Rawiwan
Yoon, In-Kyu
Ellison, Damon W.
Macareo, Louis R.
Srikiatkhachorn, Anon
Gibbons, Robert V.
Fernandez, Stefan
author_sort Hunsawong, Taweewun
collection PubMed
description Dengue, caused by dengue viruses (DENVs), is the most common arboviral disease of humans. Several dengue vaccine candidates are at different stages of clinical development and one has been licensed. Inoculation with live-attenuated DENV constructs is an approach that has been used by vaccine developers. Unfortunately, the simultaneous injection of all four attenuated DENV serotypes (DENV1-4) into a single injection site (monotopic vaccination) has been postulated to result in interference in the replication of some serotypes in favor of others, an important obstacle in obtaining a balanced immune response against all serotypes. Here, we demonstrate the virus replicative and immunostimulatory effects of polytopic monovalent dengue vaccination (PV) in which, each of the four components of the tetravalent vaccine is simultaneously delivered to four different sites versus the more traditional monotopic tetravalent vaccination (MV) in a non-human primate (NHP) model. With the exception of DENV-2, there was no significant difference in detectable viral RNA levels between PV and MV inoculation. Interestingly, longer periods of detection and higher viral RNA levels were seen in the lymph nodes of NHPs inoculated PV compared to MV. Induction of lymph node dendritic cell maturation and of blood T- and B-cell activation showed different kinetics in PV inoculated NHPs compared to MV. The MV inoculated group showed earlier maturation of dendritic cells and activation of B and T cells compared to PV inoculated NHPs. A similar kinetic difference was also observed in the cytokine response: MV induced earlier cytokine responses compared to PV. However, similar levels of DENV neutralizing antibodies were observed in PV and MV NHPs. These findings indicate that cellular immune response after vaccination may be affected by the location of inoculation. Design of vaccine delivery may need to take into account the effects of locations of vaccine delivery of multiples serotype live viral vaccine on the induction of immune response.
format Online
Article
Text
id pubmed-5367862
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-53678622017-04-07 Polytopic vaccination with a live-attenuated dengue vaccine enhances B-cell and T-cell activation, but not neutralizing antibodies Hunsawong, Taweewun Wichit, Sineewanlaya Phonpakobsin, Thipwipha Poolpanichupatam, Yongyuth Klungthong, Chonticha Latthiwongsakorn, Napaporn Thaisomboonsuk, Butsaya Im-erbsin, Rawiwan Yoon, In-Kyu Ellison, Damon W. Macareo, Louis R. Srikiatkhachorn, Anon Gibbons, Robert V. Fernandez, Stefan Heliyon Article Dengue, caused by dengue viruses (DENVs), is the most common arboviral disease of humans. Several dengue vaccine candidates are at different stages of clinical development and one has been licensed. Inoculation with live-attenuated DENV constructs is an approach that has been used by vaccine developers. Unfortunately, the simultaneous injection of all four attenuated DENV serotypes (DENV1-4) into a single injection site (monotopic vaccination) has been postulated to result in interference in the replication of some serotypes in favor of others, an important obstacle in obtaining a balanced immune response against all serotypes. Here, we demonstrate the virus replicative and immunostimulatory effects of polytopic monovalent dengue vaccination (PV) in which, each of the four components of the tetravalent vaccine is simultaneously delivered to four different sites versus the more traditional monotopic tetravalent vaccination (MV) in a non-human primate (NHP) model. With the exception of DENV-2, there was no significant difference in detectable viral RNA levels between PV and MV inoculation. Interestingly, longer periods of detection and higher viral RNA levels were seen in the lymph nodes of NHPs inoculated PV compared to MV. Induction of lymph node dendritic cell maturation and of blood T- and B-cell activation showed different kinetics in PV inoculated NHPs compared to MV. The MV inoculated group showed earlier maturation of dendritic cells and activation of B and T cells compared to PV inoculated NHPs. A similar kinetic difference was also observed in the cytokine response: MV induced earlier cytokine responses compared to PV. However, similar levels of DENV neutralizing antibodies were observed in PV and MV NHPs. These findings indicate that cellular immune response after vaccination may be affected by the location of inoculation. Design of vaccine delivery may need to take into account the effects of locations of vaccine delivery of multiples serotype live viral vaccine on the induction of immune response. Elsevier 2017-03-21 /pmc/articles/PMC5367862/ /pubmed/28393119 http://dx.doi.org/10.1016/j.heliyon.2017.e00271 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Hunsawong, Taweewun
Wichit, Sineewanlaya
Phonpakobsin, Thipwipha
Poolpanichupatam, Yongyuth
Klungthong, Chonticha
Latthiwongsakorn, Napaporn
Thaisomboonsuk, Butsaya
Im-erbsin, Rawiwan
Yoon, In-Kyu
Ellison, Damon W.
Macareo, Louis R.
Srikiatkhachorn, Anon
Gibbons, Robert V.
Fernandez, Stefan
Polytopic vaccination with a live-attenuated dengue vaccine enhances B-cell and T-cell activation, but not neutralizing antibodies
title Polytopic vaccination with a live-attenuated dengue vaccine enhances B-cell and T-cell activation, but not neutralizing antibodies
title_full Polytopic vaccination with a live-attenuated dengue vaccine enhances B-cell and T-cell activation, but not neutralizing antibodies
title_fullStr Polytopic vaccination with a live-attenuated dengue vaccine enhances B-cell and T-cell activation, but not neutralizing antibodies
title_full_unstemmed Polytopic vaccination with a live-attenuated dengue vaccine enhances B-cell and T-cell activation, but not neutralizing antibodies
title_short Polytopic vaccination with a live-attenuated dengue vaccine enhances B-cell and T-cell activation, but not neutralizing antibodies
title_sort polytopic vaccination with a live-attenuated dengue vaccine enhances b-cell and t-cell activation, but not neutralizing antibodies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367862/
https://www.ncbi.nlm.nih.gov/pubmed/28393119
http://dx.doi.org/10.1016/j.heliyon.2017.e00271
work_keys_str_mv AT hunsawongtaweewun polytopicvaccinationwithaliveattenuateddenguevaccineenhancesbcellandtcellactivationbutnotneutralizingantibodies
AT wichitsineewanlaya polytopicvaccinationwithaliveattenuateddenguevaccineenhancesbcellandtcellactivationbutnotneutralizingantibodies
AT phonpakobsinthipwipha polytopicvaccinationwithaliveattenuateddenguevaccineenhancesbcellandtcellactivationbutnotneutralizingantibodies
AT poolpanichupatamyongyuth polytopicvaccinationwithaliveattenuateddenguevaccineenhancesbcellandtcellactivationbutnotneutralizingantibodies
AT klungthongchonticha polytopicvaccinationwithaliveattenuateddenguevaccineenhancesbcellandtcellactivationbutnotneutralizingantibodies
AT latthiwongsakornnapaporn polytopicvaccinationwithaliveattenuateddenguevaccineenhancesbcellandtcellactivationbutnotneutralizingantibodies
AT thaisomboonsukbutsaya polytopicvaccinationwithaliveattenuateddenguevaccineenhancesbcellandtcellactivationbutnotneutralizingantibodies
AT imerbsinrawiwan polytopicvaccinationwithaliveattenuateddenguevaccineenhancesbcellandtcellactivationbutnotneutralizingantibodies
AT yooninkyu polytopicvaccinationwithaliveattenuateddenguevaccineenhancesbcellandtcellactivationbutnotneutralizingantibodies
AT ellisondamonw polytopicvaccinationwithaliveattenuateddenguevaccineenhancesbcellandtcellactivationbutnotneutralizingantibodies
AT macareolouisr polytopicvaccinationwithaliveattenuateddenguevaccineenhancesbcellandtcellactivationbutnotneutralizingantibodies
AT srikiatkhachornanon polytopicvaccinationwithaliveattenuateddenguevaccineenhancesbcellandtcellactivationbutnotneutralizingantibodies
AT gibbonsrobertv polytopicvaccinationwithaliveattenuateddenguevaccineenhancesbcellandtcellactivationbutnotneutralizingantibodies
AT fernandezstefan polytopicvaccinationwithaliveattenuateddenguevaccineenhancesbcellandtcellactivationbutnotneutralizingantibodies